Hints and tips:
Related Topics
...The EU accused Teva and Cephalon over the agreement in 2017 and brought formal charges this year. The EU started its probe when Teva acquired Cephalon....
...Last November, Brussels fined Teva and its former rival, now subsidiary Cephalon a combined €60.5m for conspiring to fix the price of sleep disorder drug modafinil....
...His “aha moment” came when his firm approached someone who used to work for Insys competitor Cephalon. It turned out the employee also used to work for Insys....
...The complaint centred on an agreement Teva struck with Cephalon, a US-based rival, that it would not market a cheaper generic version of Cephalon’s blockbuster modafinil drug to treat sleep disorders....
...“In this case, our preliminary finding is that Teva and Cephalon broke EU antitrust rules by agreeing on Cephalon paying Teva to keep its cheaper generic version of Cephalon’s sleep disorder drug, modafinil...
...It noted that the alleged wrongdoing occurred before it bought Cephalon and said: “We are pleased to have reached an agreement with the government.”...
...Instead, on March 21, 2014, about two years after its launch, Subsys managed to nose past Cephalon’s Actiq, then a leader in this narrow category, in number of prescriptions written, according to IMS Health...
...Israel’s biggest company by sales has taken a cautious approach to M&A ever since its $6.8bn takeover of Cephalon in 2011 failed to deliver the promised returns and saddled the company with debt....
...clashed with the directors as he sought to overhaul a company he found ill-prepared for the drug’s patent expiry, with large debts amassed from disappointing acquisitions – notably its $7bn purchase of Cephalon...
...Mr Levin steered investors away from fresh large-scale acquisitions, following its $6.5bn purchase of Cephalon. The company has been linked by analysts to other potential targets, including Amarin....
...Last year Valeant attempted a $5.7bn hostile takeover of Cephalon but was ultimately outdone by a $6.8bn offer from Teva, the Israeli generic drugmaker....
...In February 2009, the company licensed Lupuzor to Cephalon Inc and “encouraging progress” was made....
...Sales in Europe dropped 2 per cent to $1.3bn, with lower generic revenues offset by a boost in Teva’s branded products following its $6.8bn acquisition of Cephalon last year and an increased contribution...
...Generic drug companies have been looking for greater scale lately, highlighted by Watson’s acquisition of Actavis for €4.5bn in April and Teva’s $6.8bn acquisition of Cephalon last year....
...Selling a business can be a painful process, says Bryan Morton, who founded two private-equity-backed drug development companies: Zeneus Holdings, sold for $360m to Cephalon in 2005, and EUSA Pharma, bought...
...The move marks the latest in a wave of mergers in the healthcare sector in recent months and follows a failed attempt by Valeant to acquire the biotech company Cephalon last year....
...If his company’s €4.5bn purchase last week by Watson of the US signalled the former approach, Teva’s partnership unveiled last year with Procter & Gamble and its $6.8bn purchase of Cephalon pointed to the...
...Teva, by contrast, is moving away from its core generics business, spending $7bn to buy the branded company Cephalon last year and entering into a partnership with Procter & Gamble to sell over-the-counter...
...Her work has included Cephalon’s $6.8bn acquisition by Teva Pharmaceutical Industries, and her innovative approach to Burger King’s acquisition by 3G Capital Management was ranked as “Standout” in last year...
...Teva said on Monday it would pay $81.50 a share in cash for Cephalon, versus Valeant’s $73 offer....
...Valeant, the acquisitive speciality pharma company, recently turned its sights on US drugmaker Cephalon, with a $5.7bn hostile offer to acquire the biotech company....
...In a letter to Cephalon’s board before deciding to go hostile, Mr Pearson chided Cephalon for decreasing its value by spending $400m on additions to its pipeline since the time the takeover offer had been...
...Should those fans be cheering or weeping now that Israel’s Teva Pharmaceutical has outbid Valeant and gained control of Cephalon?...
International Edition